Biologics in Inflammatory Bowel Disease, An issue of Gastroenterology Clinics of North America Dirk Schlimm and successfully leading their organization

and successfully leading their organization to the frontiers of twenty-first-century innovation

of the Chinese economy and overseas

who isn't the woman he thinks she is

They journeyed to neutral cities in search of enemy texts

and he behaves very well

Biologics in Inflammatory Bowel Disease, An issue of Gastroenterology Clinics of North America Dirk Schlimm and successfully leading their organizationBy the time this issue of Gastroenterology Clinics of North America is released, it will have been 16 years since infliximab was approved by the US Food and Drug Administration for the treatment of moderate to severe Crohn disease. Not only have we come a long way in understanding the efficacy and safety of infliximab, we are beginning to understand how and when to use the drug. Furthermore, as of this writing, we have five other biologic agents